List view / Grid view
8 February 2016 | By Victoria White
NICE was concerned that alirocumab had not been compared with the combination therapy of ezetimibe plus a statin and that trials of the drug were not able to provide robust information on cardiovascular outcomes...
27 January 2016 | By Victoria White
NICE has published its final recommendations on whether six different drug treatments should be routinely funded by the NHS...
26 January 2016 | By Victoria White
NICE recommends the seven biological disease modifying drugs as options for treating severe rheumatoid arthritis which has not responded to intensive therapy with a combination of conventional DMARDs...
22 January 2016 | By Victoria White
NICE recommends that nivolumab is made available on the NHS as a treatment option for patients with advanced (unresectable or metastatic) melanoma...
13 January 2016 | By Victoria White
The new guidance combines clinical advice and public health guidance for the first time...
16 December 2015 | By Victoria White
Ciclosporin (Ikervis) is a sterile, positively charged, oil-in water, unpreserved ophthalmic emulsion that contains ciclosporin (CsA)...
11 December 2015 | By Victoria White
Sacubitril valsartan is an angiotensin receptor neprilysin inhibitor. Neprilysin inhibits the actions of peptides in dilating the blood vessels...
11 December 2015 | By Victoria White
The National Institute for Health and Care Excellence (NICE) has published draft guidance on two prostate cancer treatments - enzalutamide and abiraterone...
3 December 2015 | By Victoria White
NICE has published draft guidance as part of its highly specialised technologies programme that does not recommend Alexion’s asfotase alfa for treating paediatric-onset hypophosphatasia...
23 November 2015 | By Victoria White
The positive draft guidance follows the development of a managed access scheme by BioMarin and NHS England...
19 November 2015 | By Victoria White
The new Cancer Drugs Fund will become an instrument for the collection of important information on longer term benefits which may not be available at the time of licensing...
19 November 2015 | By Victoria White
NICE’s FAD coincides with a period of great uncertainty with the Cancer Drugs Fund deliberating again whether to remove radium-223 from the list...
18 November 2015 | By Victoria White
The NICE Committee felt the question whether Repatha (evolocumab) would reduce angina, heart attacks and strokes remains unanswered...
17 November 2015 | By Victoria White
NICE has published final draft guidance not recommending the use of Kadcyla as a treatment for a type of advanced breast cancer because the price is too high...
4 November 2015 | By Victoria White
Ikervis has been recommended for the treatment of keratitis in adults with dry eye disease who have not responded to tear substitutes...
